Related Experiment Video
Updated: May 3, 2026
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
A Vision for Gastrin-Releasing Peptide Receptor Targeting for Imaging and Therapy: Perspective from Academia and
Clément Morgat1,2, Heying Duan3, Simone Dalm4
1Nuclear Medicine Department, Bordeaux University Hospital, Bordeaux, France.
Abstract:
The gastrin-releasing peptide receptor (GRPR) is overexpressed in various cancers, including prostate cancer, breast cancer, small cell and non-small cell lung cancer, uterine and ovarian cancer, colon cancer, and gastrointestinal stromal tumors. This makes GRPR a multicancer target for theranostics, that is, molecular imaging and therapy. Here, we explore the current state of GRPR-targeted theranostics from bench to bedside, highlighting the preclinical development of various GRPR-targeting compounds and clinical applications. We review the role of GRPR-targeted molecular imaging for all stages of prostate cancer, breast cancer, and other tumors and provide a quo vadis GRPR. We aimed to offer a comprehensive overview of GRPR-targeted theranostics to inform researchers, clinicians, pharma, and regulators of the potential benefits and emerging opportunities in the pursuit of personalized precision cancer care.
Insights
Gastrin-releasing peptide receptor (GRPR) is a promising target for cancer theranostics. This review covers GRPR-targeted molecular imaging and therapy development for various cancers, advancing precision medicine.
Area of Science:
- Oncology
- Molecular Imaging
- Theranostics
Background:
- Gastrin-releasing peptide receptor (GRPR) is overexpressed in multiple cancers, including prostate, breast, lung, ovarian, and colon cancers.
- This overexpression positions GRPR as a significant target for developing novel theranostic agents.
- Current theranostic strategies leverage GRPR for both diagnostic imaging and therapeutic interventions.
Purpose of the Study:
- To provide a comprehensive overview of GRPR-targeted theranostics.
- To highlight the progression of GRPR-targeting compounds from preclinical research to clinical application.
- To inform stakeholders about the potential of GRPR theranostics in personalized cancer care.
Main Methods:
- Review of preclinical studies on GRPR-targeting compounds.
- Analysis of clinical applications of GRPR-targeted molecular imaging.
- Exploration of the current landscape and future directions of GRPR theranostics.
Main Results:
- GRPR-targeted theranostics show potential across various cancer types, including prostate and breast cancer.
- Molecular imaging using GRPR-targeting agents is effective for all cancer stages.
- Numerous GRPR-targeting compounds are advancing through preclinical development.
Conclusions:
- GRPR-targeted theranostics represent a significant opportunity for personalized precision cancer care.
- Further research and development are crucial to translate preclinical findings into widespread clinical use.
- GRPR theranostics offer a unified approach for diagnosis and treatment across multiple malignancies.
